Literature DB >> 1922591

Hyperthyroidism due to inappropriate secretion of thyroid-stimulating hormone: diagnosis and management.

A Hermus1, H Ross, P van Liessum, A Naber, A Smals, P Kloppenborg.   

Abstract

The case histories of three patients with hyperthyroidism due to overproduction of thyroid-stimulating hormone (TSH) by the pituitary gland are described. In the first patient treatment with the T3-metabolite 3,5,3'-triiodothyroacetic acid (TRIAC) led to complete clinical and biochemical normalization. In the second patient treatment with the dopaminergic agonist bromocriptine led to a temporal amelioration of hyperthyroidism. In the third patient, who was the only one with a proven pituitary adenoma, hypersecretion of TSH could be controlled by administration of the somatostatin analogue octreotide. It is emphasized that patients with this disorder should preferably not be treated with thyrostatic drugs, radioactive iodine or thyroid surgery. The success rate of these treatment modalities is lower than normal, they may lead to an increase of goiter size, and they potentially may promote growth or development of a TSH-producing adenoma. Treatment should be aimed at diminishing TSH hypersecretion.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1922591

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  3 in total

1.  Resistance to thyroid hormone associated with autoimmune thyroid disease in a Turkish family.

Authors:  D Y Aksoy; A Gurlek; U Ringkananont; R E Weiss; S Refetoff
Journal:  J Endocrinol Invest       Date:  2005-04       Impact factor: 4.256

2.  Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with a TSH/PRL-producing pituitary macroadenoma.

Authors:  N P Verhoeff; F J Bemelman; W M Wiersinga; E A van Royen
Journal:  Eur J Nucl Med       Date:  1993-06

3.  Genetic analysis of 29 kindreds with generalized and pituitary resistance to thyroid hormone. Identification of thirteen novel mutations in the thyroid hormone receptor beta gene.

Authors:  M Adams; C Matthews; T N Collingwood; Y Tone; P Beck-Peccoz; K K Chatterjee
Journal:  J Clin Invest       Date:  1994-08       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.